Home

For NAIDOC Week 2022, join us on this immersive virtual tour of Peter Mac's Aboriginal art collection.

Chronic lymphocytic leukaemia (CLL) patients who are refractory or resistant to treatment can be encouraged by data showing significantly longer survival without disease progression with a treatment combining venetoclax and rituximab compared to treatment with bendamustine plus rituximab.

Peter Mac's Associate Professor Jane Oliaro and Professor Ricky Johnstone have been awarded funding for two different blood cancer research projects.